Dr. Yelena Janjigian, MD
Claim this profileMemorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Studies Esophageal Cancer
Studies Stomach Cancer
6 reported clinical trials
11 drugs studied
Area of expertise
1Esophageal Cancer
Stage IV
HER2 positive
2Stomach Cancer
Stage IV
HER2 positive
Affiliated Hospitals
Clinical Trials Yelena Janjigian, MD is currently running
Pembrolizumab + Trastuzumab + Chemotherapy
for Esophageal Cancer
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
Recruiting1 award Phase 27 criteria
Combination Therapy
for Esophageal and Stomach Cancers
This trial is testing a combination of new and existing drugs to treat patients whose disease isn't responding well to standard treatments. The drugs work by either boosting the immune system or directly attacking cancer cells. The goal is to find more effective treatment options for these patients.
Recruiting1 award Phase 2
More about Yelena Janjigian, MD
Clinical Trial Related5 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Yelena Janjigian, MD has experience with
- Pembrolizumab
- Trastuzumab
- Nivolumab
- FOLFOX Chemotherapy With Oxaliplatin
- Regorafenib
- 18F-BMS-986229
Breakdown of trials Yelena Janjigian, MD has run
Esophageal Cancer
- A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
- Nivolumab + FOLFOX + Regorafenib for Esophageal Cancer
- A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Stomach Cancer
- A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
- A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Pembrolizumab + Trastuzumab + Chemotherapy for Esophageal Cancer
Gastroesophageal Junction Adenocarcinoma
- A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
- A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
- Combination Therapy for Esophageal and Stomach Cancers
Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yelena Janjigian, MD specialize in?
Yelena Janjigian, MD focuses on Esophageal Cancer and Stomach Cancer. In particular, much of their work with Esophageal Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Yelena Janjigian, MD currently recruiting for clinical trials?
Yes, Yelena Janjigian, MD is currently recruiting for 2 clinical trials in Basking Ridge New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Yelena Janjigian, MD has studied deeply?
Yes, Yelena Janjigian, MD has studied treatments such as Pembrolizumab, Trastuzumab, Nivolumab.
What is the best way to schedule an appointment with Yelena Janjigian, MD?
Apply for one of the trials that Yelena Janjigian, MD is conducting.
What is the office address of Yelena Janjigian, MD?
The office of Yelena Janjigian, MD is located at: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States. This is the address for their practice at the Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.